PMID- 15455388
OWN - NLM
STAT- MEDLINE
DCOM- 20050119
LR  - 20220317
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 113
IP  - 4
DP  - 2005 Feb 10
TI  - C-Met overexpression in node-positive breast cancer identifies patients with poor 
      clinical outcome independent of Her2/neu.
PG  - 678-82
AB  - Receptor tyrosine kinases play an important role in malignant transformation of 
      epithelial cells by activating signal transduction pathways important for 
      proliferation, invasion and metastasis. In a pilot study (n = 40), we evaluated 
      expression of the c-Met and Her2/neu receptor tyrosine kinases and the c-Met 
      ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers 
      and their lymph node metastases using both conventional immunohistochemistry and 
      confocal immunofluorescence. Neither c-Met and HGF/SF nor Her2/neu expression 
      correlated with established prognostic factors such as age, lymph node 
      involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or 
      grade. Both staining methods confirmed a significant correlation between c-Met 
      overexpression and a high risk of disease progression. Furthermore, among tumors 
      with c-Met overexpression, only 50% also overexpress Her2/neu, thus identifying a 
      subset of patients with aggressive disease in addition to Her2/neu. Median 
      disease-free survival in patients with c-Met overexpressing tumors was 8 months 
      compared to 53 months when c-Met expression was low (p = 0.037; RR = 3.0). This 
      significant impact of c-Met on tumor aggressiveness independent of Her2/neu was 
      also confirmed by multivariate analysis. In conclusion, the role of c-Met 
      expression as a prognostic variable and consequently as an interesting target for 
      novel therapeutic approaches deserves further analysis in a larger cohort of 
      patients.
FAU - Lengyel, Ernst
AU  - Lengyel E
AD  - Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, 
      University of Chicago, Mail Code 2050, 5841 South Maryland Avenue, Chicago, IL 
      60637, USA. elengyel@uchicago.edu
FAU - Prechtel, Dieter
AU  - Prechtel D
FAU - Resau, James H
AU  - Resau JH
FAU - Gauger, Katja
AU  - Gauger K
FAU - Welk, Anita
AU  - Welk A
FAU - Lindemann, Kristina
AU  - Lindemann K
FAU - Salanti, Georgia
AU  - Salanti G
FAU - Richter, Thomas
AU  - Richter T
FAU - Knudsen, Beatrice
AU  - Knudsen B
FAU - Vande Woude, George F
AU  - Vande Woude GF
FAU - Harbeck, Nadia
AU  - Harbeck N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Ligands)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/drug therapy/*metabolism/*pathology
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Fibrocystic Breast Disease/drug therapy/metabolism/pathology
MH  - Hepatocyte Growth Factor/metabolism
MH  - Humans
MH  - Hyperplasia/drug therapy/metabolism/pathology
MH  - Ligands
MH  - Lymph Nodes/pathology
MH  - Lymphatic Metastasis/*pathology
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Pilot Projects
MH  - Proto-Oncogene Proteins c-met/*metabolism
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Risk Factors
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2004/09/30 05:00
MHDA- 2005/01/20 09:00
CRDT- 2004/09/30 05:00
PHST- 2004/09/30 05:00 [pubmed]
PHST- 2005/01/20 09:00 [medline]
PHST- 2004/09/30 05:00 [entrez]
AID - 10.1002/ijc.20598 [doi]
PST - ppublish
SO  - Int J Cancer. 2005 Feb 10;113(4):678-82. doi: 10.1002/ijc.20598.